MS relapse

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. People with …

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference.

The National Institute for Health and Care Excellence (NICE) will not recommend that Ponvory (ponesimod) be added to the National Health Service (NHS) of England and Wales for people with active, relapsing forms of multiple sclerosis (MS). The provisional decision, made because Ponvory was not found to be…

I am having an MS relapse, my first in three years. In the first two years after I was diagnosed with relapsing-remitting MS in early 2017, I relapsed every two or three months. It got to the point that I couldn’t tell where one relapse began and another ended.

TG Therapeutics  has applied to the U.S. Food and Drug Administration (FDA) for approval of ublituximab, the company’s investigational anti-CD20 monoclonal antibody therapy for relapsing forms of multiple sclerosis (RMS). Its application was based on data from the ULTIMATE 1 (NCT03277261) and ULTIMATE 2 (NCT03277248) Phase…

The first patient who completed the ProTEct-MS Phase 2 clinical trial assessing temelimab as a treatment for relapsing forms of multiple sclerosis (MS) has entered the trial’s extension part. In the open-label extension trial, patients will switch to or continue to receive temelimab at least until next spring, when…

First-line treatment with Tecfidera (dimethyl fumarate) leads to a lower rate of relapses in people with relapsing-remitting multiple sclerosis (RRMS) than does treatment with Aubagio (teriflunomide) or injectable immunomodulators, according to an analysis of insurance data from France. “These data will be useful to feed into physician…

Women with relapsing-remitting multiple sclerosis (MS) who suspend their use of fingolimod — sold as Gilenya, among others — to conceive or during the early stages of pregnancy have a significantly higher risk of relapse during and after pregnancy, a new study finds. Stopping fingolimod resulted in a…

Risk of MS Relapse Not Increased by COVID-19 Vaccine, Study Finds This new information about one of the COVID-19 vaccines supports what doctors have been saying all along. So, why do some people continue to believe the vaccines raise the risk of a relapse? In my personal, nonscientific opinion,…

Winston Churchill once wrote, “I pass with relief from the tossing sea of Cause and Theory to the firm ground of Result and Fact.” This very much sums me up as a person. It was also how I felt when I was diagnosed with relapsing-remitting MS 10 months…

Getting the Pfizer-BioNTech vaccine for COVID-19 does not increase the risk of multiple sclerosis (MS) relapses in the two months following vaccination, according to a new study. The results support recommending COVID-19 vaccines for people with MS, its researchers said. “The incidence of relapses in the 2 months before and…

Ocrevus Reduces MS Relapse Risk, But Linked to More Hospitalizations As you can see from the first two paragraphs of this story, these hospitalizations occurred most frequently in older people with MS. Yet, as these researchers point out, the criteria for selecting the people who participated in Ocrevus’ clinical…

Ocrevus (ocrelizumab) reduces relapse risk and slows disability progression in multiple sclerosis (MS) but also is associated with higher hospitalization rates in older people with relapsing forms of the disease, a new observational study reports. Hospitalizations — which occurred mainly due to urinary tract infections — were more frequent…

People with multiple sclerosis (MS) who experienced relapses in the previous year are more likely to have better adherence to their current treatment regimen, a cross-sectional study reports. The research also identified associations between treatment adherence and a lower body mass index (BMI), and between better perceived mental health…

It’s with a heavy heart that I write this. I don’t want to, but I have to do what’s right. This will be my last column. Lately, things have been crazy busy for me, with a mix of expected events, such as moving to a new home, and a few unexpected…

Larger declines with treatment in blood levels of neurofilament light chain (NfL), a marker of nerve cell damage, are associated with fewer brain lesions, less brain shrinkage, and lower relapse rates in people with relapsing forms of multiple sclerosis (MS), a study reported. These results, based on a post-hoc analysis…

My obsession with numbers has continued since my latest MS relapses, but now I’ve taken it to a whole new level. A few months ago, I explained in a column that my husband had filled our house with clocks after reading “Atomic Habits” by James Clear, which…

High-potency therapies are more effective at reducing the frequency of symptom relapses in people with secondary progressive multiple sclerosis (SPMS) than low-potency medications, a 10-year study showed. Notably, there was no difference in the effectiveness of either high- or low-potency medicines to limit the progression of disability. “When the…

Sleep deprivation may worsen memory in people with clinically isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS), a new observational study suggests. A link also was observed between a lack of sleep and worse cognitive efficiency in early MS, but that association was caused by the worse moods…

In clinical trials, the investigational anti-CD20 therapy ublituximab was the first to push the annualized relapse rate (ARR) below the 0.1 threshold among patients with relapsing forms of multiple sclerosis (MS), while improving disability outcomes in a significant proportion of patients. “The [relapse] rate was below a tenth…

A numb, weak leg. Yay. Another thing to add to the list of crappy challenges I’ve had to face this year. If you ask me, it’s all been a bit too much, and I’d like to get off this ride and get my money back, please. I recently rang my…

In the four decades I’ve lived with MS, I’d never before experienced a serious case of vertigo. I’ve occasionally felt a little spacey. In fact, mild dizziness while traveling home from a business convention is one of the things that led to my MS diagnosis in 1980. But vertigo is…

High levels of kappa-free light chains, or kappa-FLC, in the cerebrospinal fluid (CSF) — the liquid surrounding the brain and spinal cord — may help identify people with clinically isolated syndrome (CIS) who will progress sooner to multiple sclerosis (MS), a study reports. Overall, those with a high…

In the OPTIMUM clinical trial, Ponvory (ponesimod) significantly outperformed Aubagio (teriflunomide) in reducing relapse rates, fatigue, and evidence of brain damage among people with relapsing multiple sclerosis (MS). Based on these results, Ponvory has now been approved in the U.S. and the European Union as a treatment…

Many years ago I thrust myself into the Edinburgh International Festival. For the many who have never heard of it: It’s the largest arts festival in the world, encompassing theater, mime, dance, comedy, film, books, and sometimes even a splash of opera. For some reason I even sat through…

People with  multiple sclerosis (MS) who are using a disease-modifying therapy — and are at a younger age — when they have a relapse within the first three years of their disease course are more likely to recover completely, lowering their risk of long-term, 10-year disability, a study suggests. Complete recovery…

Something crazy happened: I felt the strength slowly run out of my leg. It was like it needed a serious charge, but the charging port was nonexistent. I’d received some bad news a few days before that, and I think the stress of the news caused a flare-up. My…

The U.S. Food and Drug Administration (FDA) has rejected an application requesting the expansion of Aubagio (teriflunomide) for the treatment of children and adolescents, ages 10 to 17, with relapsing forms of multiple sclerosis (MS). “The FDA deemed the data submitted were not sufficient to obtain approval of…

Urinary problems, such as an urgency to urinate or a feeling of incomplete urination, are common among people with multiple sclerosis (MS), impacting more than half of patients, according to a large study in Italy. The researchers noted that urinary disorders…

Well, this was a first. I’d fallen backward once in my power wheelchair. That was in the back of our mobility van. Hubris told me I could get away with just holding on to the handgrip for a few hundred meters. As ever, hubris was wrong! About six months…